Genmab A/S (OTCMKTS:GNMSF - Get Free Report)'s share price crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $208.09 and traded as high as $215.30. Genmab A/S shares last traded at $212.55, with a volume of 134 shares traded.
Genmab A/S Stock Up 1.1%
The firm has a market cap of $14.20 billion, a P/E ratio of 12.19 and a beta of 0.91. The business has a fifty day moving average of $208.14 and a 200 day moving average of $205.77.
Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $3.05 EPS for the quarter, topping analysts' consensus estimates of $1.88 by $1.17. Genmab A/S had a return on equity of 19.23% and a net margin of 35.11%. The business had revenue of $765.14 million during the quarter, compared to analysts' expectations of $761.09 million.
About Genmab A/S
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Further Reading
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
